한글목차

생체 흡수성 관상동맥 스텐트 세계 시장은 2024년 5억 5,009만 달러에 달했으며, 예측 기간 동안 큰 폭으로 성장하여 2030년까지 10.25%의 연평균 복합 성장률(CAGR)을 보일 것으로 예측됩니다.

최근 심장병학의 발전은 관상동맥질환(CAD) 환자의 예후와 삶의 질을 크게 향상시키고 있습니다. 이러한 기술 혁신 속에서 생체 흡수성 관상동맥 스텐트는 CAD 치료의 패러다임을 바꾸는 혁신적인 솔루션으로 등장했습니다. 기존의 금속 스텐트와는 달리, 이 스텐트는 동맥을 지지하는 기능을 수행한 후 체내에서 서서히 용해되도록 설계되어 있습니다.

시장 성장 촉진요인

심혈관 질환(CVDs)의 유병률 증가

시장의 과제

효과와 안전에 대한 우려

시장 동향

기술 발전

목차

제1장 제품 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 생체흡수성 관상동맥 스텐트 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 브랜드별(Magmaris, Magnitude, MeRes-100, DESolve, 기타)
  • 최종사용자별(병원 및 진료소, 외래 진료 센터, 기타)
  • 지역별
  • 기업별(2024년)
• 시장 맵

제6장 북미의 생체흡수성 관상동맥 스텐트 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 미국
  • 캐나다
  • 멕시코

제7장 유럽의 생체흡수성 관상동맥 스텐트 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 독일
  • 영국
  • 이탈리아
  • 프랑스
  • 스페인

제8장 아시아태평양의 생체흡수성 관상동맥 스텐트 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 일본
  • 한국
  • 호주

제9장 남미의 생체흡수성 관상동맥 스텐트 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 생체흡수성 관상동맥 스텐트 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트(UAE)

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 최근 동향
• 제품 출시
• 인수합병(M&A)

제13장 세계의 생체흡수성 관상동맥 스텐트 시장 : SWOT 분석

제14장 경쟁 구도

• BIOTRONIK SE & Co. KG
• Meril Life Sciences Pvt. Ltd
• Elixir Medical Corporation.
• Reva Medical, LLC
• Terumo Corporation
• Lepu Medical Technology(Beijing) Co.,Ltd
• MicroPort Scientific Corporation
• LifeTech Scientific Corporation
• Boston Scientific Corporation
• Medtronic plc

제15장 전략적 제안

제16장 회사 소개 및 면책조항

영문목차

The Global Bioresorbable Coronary Stents Market was valued at USD 550.09 million in 2024 and is projected to witness substantial growth during the forecast period, registering a CAGR of 10.25% through 2030. Recent advancements in cardiology have significantly enhanced patient outcomes and quality of life for individuals suffering from coronary artery disease (CAD). Among these innovations, bioresorbable coronary stents have emerged as a transformative solution, marking a paradigm shift in CAD treatment. Unlike traditional metallic stents, these stents are designed to gradually dissolve within the body after fulfilling their function of arterial support.

Market Drivers

Increasing Prevalence of Cardiovascular Diseases (CVDs)

The growing global incidence of cardiovascular diseases represents a key driver for market expansion. CVDs remain the leading cause of death globally, responsible for 17.9 million deaths in 2019-approximately 32% of global mortality. Notably, 85% of these fatalities were due to heart attacks and strokes. Furthermore, over 75% of CVD-related deaths occur in low- and middle-income countries, highlighting a critical gap in healthcare infrastructure and access to advanced cardiac care.

The rising number of patients diagnosed with coronary artery disease (CAD) has spurred demand for innovative treatment approaches like bioresorbable coronary stents. In 2022, the global prevalence of CAD was estimated at 315 million cases, with a 95% uncertainty range of 273 to 362 million. The age-standardized prevalence rate was recorded at 3,605 per 100,000 individuals, underscoring the widespread nature of the disease.

The aging global population is a significant contributing factor, as age is the most prominent non-modifiable risk factor for CAD and related cardiovascular conditions. According to the American Heart Association (AHA) 2019 update, 31% of men and 25.4% of women aged 80 and above are diagnosed with CAD. In addition, lifestyle factors such as hypertension, diabetes, obesity, and physical inactivity continue to escalate the global burden of cardiovascular risk, further supporting the shift toward bioresorbable stent adoption.

Market Challenges

Efficacy and Safety Concerns

Despite their promising potential, bioresorbable coronary stents face ongoing scrutiny regarding their clinical safety and efficacy. Some trials have raised concerns about the risk of stent thrombosis-the formation of blood clots within or near the stent-leading to potentially life-threatening complications. These concerns have prompted a comparative evaluation against conventional metallic stents, particularly in terms of long-term safety outcomes.

Market Trends

Technological Advancements

Rapid innovation in medical technology has significantly influenced the development and adoption of bioresorbable coronary stents. Continuous advancements in material science have enabled the creation of stents that maintain mechanical strength during initial healing phases while degrading safely thereafter. The use of biocompatible materials has improved both patient outcomes and procedural safety.

State-of-the-art manufacturing techniques such as 3D printing and laser cutting allow for the production of highly intricate stent designs, optimizing both radial strength and vascular conformability. Many stents are now developed with drug-eluting properties, enabling the controlled release of therapeutic agents to reduce risks of restenosis and inflammation.

Innovations in intravascular imaging technologies, such as intravascular ultrasound (IVUS) and optical coherence tomography (OCT), have further enhanced procedural accuracy by providing high-resolution, real-time visualization of stent deployment. This precision supports optimal placement and expands the therapeutic potential of bioresorbable stents.

Ongoing clinical research and trials continue to refine stent designs and validate long-term outcomes, offering valuable data that guide next-generation product development and regulatory approvals.

Key Market Players

• BIOTRONIK SE & Co. KG
• Meril Life Sciences Pvt. Ltd
• Elixir Medical Corporation.
• Reva Medical, LLC
• Terumo Corporation
• Lepu Medical Technology (Beijing)Co.,Ltd
• MicroPort Scientific Corporation
• LifeTech Scientific Corporation
• Boston Scientific Corporation
• Medtronic plc

Report Scope:

In this report, the Global Bioresorbable Coronary Stents Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Bioresorbable Coronary Stents Market, By Brand:

• Magmaris
• Magnitude
• MeRes-100
• DESolve
• Others

Bioresorbable Coronary Stents Market, By End User:

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Bioresorbable Coronary Stents Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Bioresorbable Coronary Stents Market.

Available Customizations:

Global Bioresorbable Coronary Stents market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Bioresorbable Coronary Stents Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Brand (Magmaris, Magnitude, MeRes-100, DESolve, Others)
  • 5.2.2. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Bioresorbable Coronary Stents Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Brand
  • 6.2.2. By End User
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Bioresorbable Coronary Stents Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Brand
      • 6.3.1.2.2. By End User
  • 6.3.2. Canada Bioresorbable Coronary Stents Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Brand
      • 6.3.2.2.2. By End User
  • 6.3.3. Mexico Bioresorbable Coronary Stents Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Brand
      • 6.3.3.2.2. By End User

7. Europe Bioresorbable Coronary Stents Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Brand
  • 7.2.2. By End User
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Bioresorbable Coronary Stents Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Brand
      • 7.3.1.2.2. By End User
  • 7.3.2. United Kingdom Bioresorbable Coronary Stents Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Brand
      • 7.3.2.2.2. By End User
  • 7.3.3. Italy Bioresorbable Coronary Stents Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Brand
      • 7.3.3.2.2. By End User
  • 7.3.4. France Bioresorbable Coronary Stents Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Brand
      • 7.3.4.2.2. By End User
  • 7.3.5. Spain Bioresorbable Coronary Stents Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Brand
      • 7.3.5.2.2. By End User

8. Asia-Pacific Bioresorbable Coronary Stents Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Brand
  • 8.2.2. By End User
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Bioresorbable Coronary Stents Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Brand
      • 8.3.1.2.2. By End User
  • 8.3.2. India Bioresorbable Coronary Stents Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Brand
      • 8.3.2.2.2. By End User
  • 8.3.3. Japan Bioresorbable Coronary Stents Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Brand
      • 8.3.3.2.2. By End User
  • 8.3.4. South Korea Bioresorbable Coronary Stents Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Brand
      • 8.3.4.2.2. By End User
  • 8.3.5. Australia Bioresorbable Coronary Stents Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Brand
      • 8.3.5.2.2. By End User

9. South America Bioresorbable Coronary Stents Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Brand
  • 9.2.2. By End User
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Bioresorbable Coronary Stents Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Brand
      • 9.3.1.2.2. By End User
  • 9.3.2. Argentina Bioresorbable Coronary Stents Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Brand
      • 9.3.2.2.2. By End User
  • 9.3.3. Colombia Bioresorbable Coronary Stents Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Brand
      • 9.3.3.2.2. By End User

10. Middle East and Africa Bioresorbable Coronary Stents Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Brand
  • 10.2.2. By End User
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Bioresorbable Coronary Stents Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Brand
      • 10.3.1.2.2. By End User
  • 10.3.2. Saudi Arabia Bioresorbable Coronary Stents Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Brand
      • 10.3.2.2.2. By End User
  • 10.3.3. UAE Bioresorbable Coronary Stents Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Brand
      • 10.3.3.2.2. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Bioresorbable Coronary Stents Market: SWOT Analysis

14. Competitive Landscape

• 14.1. BIOTRONIK SE & Co. KG
  • 14.1.1. Business Overview
  • 14.1.2. Product & Service Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Financials (If Listed)
  • 14.1.5. Key Personnel
  • 14.1.6. SWOT Analysis
• 14.2. Meril Life Sciences Pvt. Ltd
• 14.3. Elixir Medical Corporation.
• 14.4. Reva Medical, LLC
• 14.5. Terumo Corporation
• 14.6. Lepu Medical Technology (Beijing)Co.,Ltd
• 14.7. MicroPort Scientific Corporation
• 14.8. LifeTech Scientific Corporation
• 14.9. Boston Scientific Corporation
• 14.10.Medtronic plc

15. Strategic Recommendations

16. About Us & Disclaimer